Key Highlights
- Shares fell 0.05% to USD 438.60 on relative Volume of 1.98.
- Third-quarter revenues were USD 10,365 million, with Net Income of USD 3,864 million.
- 2026 Revenue guidance was raised to USD 38.9 billion to USD 39.7 billion.
- Nine-month intangible Impairment was USD 63 million, against USD 1,200 million.
Amgen (NASDAQ:AMGN) shares traded at USD 438.60 on November 20, 2026, down 0.05%, with a relative volume at time of 1.98. The company has given no reason for the heavy trading. Its report for the quarter ended September 30, 2026 and its raised 2026 guidance both came on November 4, so those events predate the session.
Amgen is a Delaware corporation based in Thousand Oaks, California. It discovers, develops, manufactures and delivers human therapeutics, with products including Repatha, Prolia, EVENITY, TEZSPIRE, ENBREL, Otezla, BLINCYTO, KRYSTEXXA, XGEVA, UPLIZNA, KYPROLIS and Vectibix. It reports as one segment, and its fiscal year ends on December 31.
The Third Quarter
Total revenues were USD 10,365 million versus USD 9,557 million. Product sales were USD 9,883 million versus USD 9,137 million, and other revenues were USD 482 million versus USD 420 million. Cost of sales was USD 2,788 million versus USD 3,082 million.
Research and development expenses were USD 2,111 million versus USD 1,900 million, and selling, general and administrative expenses were USD 1,680 million versus USD 1,720 million. Other operating expenses were USD 76 million versus USD 329 million. Operating Income was USD 3,710 million versus USD 2,526 million.
Interest expense, net was USD 653 million, and other income, net was USD 1,629 million versus USD 2,080 million. Income before taxes was USD 4,686 million, with a tax provision of USD 822 million. Net income was USD 3,864 million versus USD 3,216 million, or USD 7.08 per diluted share versus USD 5.93.
Product sales were USD 1,085 million for Repatha, USD 751 million for EVENITY, USD 632 million for Prolia, USD 611 million for ENBREL, USD 538 million for TEZSPIRE and USD 481 million for Otezla. A year earlier they were USD 794 million, USD 541 million, USD 1,139 million, USD 580 million, USD 377 million and USD 585 million.
Nine Months and the Impairment
Total revenues were USD 29,037 million versus USD 26,885 million, and product sales were USD 27,638 million versus USD 25,781 million. Operating income was USD 9,890 million versus USD 6,360 million. Net income was USD 8,058 million versus USD 6,378 million, or USD 14.79 per diluted share versus USD 11.77.
The Cash Flow Statement shows impairment of intangible Assets of USD 63 million, compared with USD 1,200 million a year earlier, when Otezla charges followed its selection for price setting under the Inflation Reduction Act. The company expects further declines in Otezla's net selling price from 2027 under Medicare price setting.
Cash Flow and Balance Sheet
Operating activities provided USD 10,432 million versus USD 8,355 million. Property, plant and equipment purchases were USD 1,812 million, and dividends paid were USD 4,083 million versus USD 3,841 million. Debt issuance brought in USD 3,964 million, and repayments were USD 3,883 million.
Cash and cash equivalents were USD 12,621 million versus USD 8,525 million at year end. Total assets were USD 96,048 million versus USD 90,586 million, and stockholders' Equity was USD 14,352 million versus USD 8,658 million. Long-term debt was USD 51,609 million versus USD 50,005 million, and its current portion was USD 2,398 million versus USD 4,599 million.
Raised Guidance
On the November 4 call, management raised its 2026 ranges to total revenues of USD 38.9 billion to USD 39.7 billion and non-GAAP Earnings Per Share of USD 22.90 to USD 23.70. It expects operating expenses to rise sequentially in the fourth quarter and does not anticipate a step-down in Operating Margin in 2027 against 2026 guidance.
What to Watch Next for Amgen
The company has given no reason for the November 20 volume, and its earnings and guidance were released earlier. The reported record combines higher revenue and profit, a much larger cash balance and slightly higher long-term debt. Otezla pricing in 2027 and fourth-quarter operating expenses are the points to follow.






Please wait processing your request...